The July 2026 FDA Advisory Votes on BPC-157, TB-500, MOTS-c and Semax: What Changed and What Did Not

For most of the past decade, the regulatory story of peptides such as BPC-157 and TB-500 in the United States has been one of quiet exclusion: nominated for compounding, parked in “Category 2” of FDA’s interim policy for safety concerns, and effectively off-limits to pharmacies. That story took a turn in 2026. In February the Department of Health and Human Services announced that a group of peptides would be moved out of Category 2, and in July FDA convened its Pharmacy Compounding Advisory Committee (PCAC) to consider seven of them for formal inclusion on the 503A Bulks List. The committee, by slim margins and against the written advice of FDA’s scientific staff, recommended six. This note explains what happened, what the 503A list is, why the votes matter less than headlines suggest, and why none of it changes how research material should be handled or described.

What the 503A Bulks List is

Section 503A of the Federal Food, Drug, and Cosmetic Act allows state-licensed pharmacists and physicians to compound drugs for identified patients without those products going through FDA approval, provided certain conditions are met. One condition concerns the raw ingredient. A bulk drug substance used in 503A compounding must either have a USP or NF monograph, be a component of an FDA-approved drug, or appear on a list FDA develops through rulemaking, the 503A Bulks List.¹

Because building that list has been slow, FDA has operated an interim policy that sorts nominated substances into three categories. Category 1 substances were nominated with adequate information and without identified safety concerns; FDA does not intend to take enforcement action against their use in compounding while evaluation continues. Category 2 substances are those for which FDA identified significant safety risks. Category 3 substances were nominated with insufficient supporting information.¹ None of these categories is approval. A Category 1 placement is a statement about enforcement discretion, not a finding of safety or effectiveness.

The peptides discussed in July had spent years in Category 2. FDA’s own withdrawn-nominations page, current as of April 22, 2026, lists BPC-157, CJC-1295, GHK-Cu, MOTS-c, Semax and thymosin beta-4 as substances whose nominations were withdrawn, while ipamorelin acetate, GHRP-2, GHRP-6 and kisspeptin-10 remained in Category 2.² The May 14, 2026 category document adds a wrinkle for GHK-Cu: the nominator clarified that it wished to withdraw only the injectable route, so GHK-Cu for non-injectable routes was returned to Category 1, with FDA stating it intends to consult PCAC on it before February 2027.³

What was on the agenda

FDA published the meeting notice, agenda and a briefing document ahead of the two-day session at its White Oak campus. The agenda covered seven bulk drug substances, each in both free-base and acetate form, with a proposed clinical use attached to each nomination:^4,5

Day	Substance	Nominated use	FDA staff recommendation	Committee vote
July 23	BPC-157	Ulcerative colitis	Do not include	8–6 in favor, 1 abstention
July 23	KPV	Wound healing, inflammatory conditions	Do not include	8–6 in favor, 1 abstention
July 23	TB-500	Wound healing	Do not include	8–6 in favor, 1 abstention
July 23	MOTS-c	Obesity, osteoporosis	Do not include	7–5 in favor, 2 abstentions
July 24	Emideltide (DSIP)	Opioid withdrawal, insomnia, narcolepsy	Do not include	Rejected, 7–6 with 1 abstention
July 24	Semax	Cerebral ischemia, migraine, trigeminal neuralgia	Do not include	Recommended, narrow margin
July 24	Epitalon	Insomnia	Do not include	Recommended, narrow margin

Vote counts for day one are from trade reporting of the session; day-two counts for Semax and epitalon were described by multiple outlets only as narrow, and the emideltide result as 7–6 against.^6,7,8

What FDA’s reviewers said

The briefing document is unambiguous. FDA proposed that none of the seven substances, in either salt form, be included on the 503A Bulks List, fourteen separate recommendations against. The agency also noted that the original nominators had withdrawn their submissions, but that FDA was “electing to proceed” with presenting all seven to the committee anyway.⁵ The evaluation framework FDA applies is the same for every candidate: physical and chemical characterization, safety, available evidence of effectiveness for the proposed use, and historical use in compounding.

Reporting from the meeting captured the character of the staff objections. An FDA official is quoted as saying the agency had “never faced a problem of, ‘What is it?'”, a reference to the fact that several of these peptides lack a universally accepted chemical identity, salt form and impurity profile, which makes evaluating safety and effectiveness difficult before one even reaches the clinical data.⁶ Reviewers also cited batch variability and the potential for immunogenic responses to peptide impurities.⁷ Those are, notably, the same analytical concerns that motivate third-party testing of research material; see why third-party lab testing matters and the COA library.

An advisory committee can recommend that a substance be listed; only rulemaking can list it, and only approval can make it a drug.

Why the votes were controversial

Two features of the meeting drew comment. First, the committee’s recommendations ran directly counter to FDA’s uniform written opposition, which is unusual for PCAC. Second, the composition of the panel: reporting indicated that seven of fourteen members work for or operate peptide-therapy businesses or clinics, though an HHS spokesperson said all members passed standard ethics review.⁷ One dissenting member is quoted as worrying that the committee was “responding to market-induced demand rather than a decision based in solid science.”⁷

The political backdrop matters for interpretation. The HHS Secretary had publicly supported easing peptide restrictions and, in April, moved a dozen peptides out of Category 2. Supporters framed listing as harm reduction, moving people from unmonitored online products to licensed pharmacies with prescriptions. Critics framed it as creating a back door for unapproved drugs. Both framings are about compounded prescription products; neither is about research supply.

What happens next, and how long it takes

A PCAC recommendation is advice. For a substance to actually join the 503A Bulks List, FDA must decide whether to accept the recommendation, publish a proposed rule in the Federal Register, take public comment, respond to that comment and issue a final rule.⁸ Trade estimates for that process ranged from roughly eight to twelve months to, on more cautious analyses, into 2027 or 2028.^6,7 As of early September 2026, none of the six peptides has been added to the list, and none is an FDA-approved drug.⁸

In the interim, the practical status of these substances for compounders is governed by the category system, not by the vote. Substances that left Category 2 in the spring sit under enforcement discretion, subject to conditions; the July votes did not alter that, and a final rule could in principle still decline to list any of them.

What this means for research peptides

It is tempting to read the July votes as a change in the legal standing of BPC-157 or TB-500 generally. They are not. Three points follow directly from the regulatory structure.

First, the 503A pathway concerns pharmacies compounding a prescription drug for a specific patient. Research-grade material sold for laboratory use is not a compounded drug and is not what the committee was voting on. Second, the votes leave the underlying science where it was: for BPC-157, human exposure data come from fewer than thirty subjects across three uncontrolled pilots, as a May 2026 review in Pharmaceutics documented,⁹ and for TB-500 a June 2026 scoping review found a single study specific to the synthetic fragment.¹⁰ Third, the analytical questions FDA staff raised, what exactly is in the vial, in what salt form, with what impurities, apply to any source of these peptides. A research supplier cannot answer them with a vote; it can only answer them with batch-specific testing. For an overview of what the preclinical literature on these compounds does and does not show, see the BPC-157 research overview and the TB-500 and thymosin beta-4 note.

Wednesday’s position is unchanged by the meeting. The compounds below are supplied for research use only, are not approved drugs, and are not intended to diagnose, treat or prevent any condition. The relevant news is that a public record now exists, the briefing document, the transcript, the votes, of how the agency and its advisors weigh the evidence for these peptides. That record is worth reading in full.

Frequently asked questions

Did the FDA approve BPC-157 in July 2026?

No. An FDA advisory committee voted 8–6 to recommend that BPC-157 be considered for the 503A Bulks List, which governs which bulk substances pharmacies may compound. The recommendation is non-binding, FDA’s own reviewers opposed it, and no rule has been issued. BPC-157 is not an FDA-approved drug.

What is the difference between the 503A Bulks List and drug approval?

Drug approval means FDA has reviewed a specific product’s safety and effectiveness data for a specific indication. The 503A Bulks List only identifies raw substances that licensed pharmacies may use when compounding a prescription for an individual patient. A substance can be on the list without any approved drug containing it existing.

Which peptides did the PCAC recommend in July 2026?

BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon were recommended, all by narrow margins. Emideltide (DSIP) was rejected 7–6 with one abstention. FDA’s briefing document had recommended against including all seven.

When could these peptides actually be added to the 503A list?

Only after FDA publishes a proposed rule, takes public comment and issues a final rule. Estimates at the time of the meeting ranged from under a year to 2027–2028, and FDA is not obliged to follow the committee.

Does the vote change anything for research-use peptides?

No. The vote concerns pharmacy compounding under prescription. Research-grade material remains unapproved and for laboratory use only. The analytical concerns FDA staff raised about identity and impurities are the same ones that make batch-specific third-party testing important for research suppliers.

References & further reading

1. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov
2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Content current as of April 22, 2026. fda.gov
3. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: category listing. Updated May 14, 2026. fda.gov (PDF)
4. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov; agenda: fda.gov (PDF)
5. U.S. Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, July 23–24, 2026. fda.gov (PDF)
6. PharmExec. FDA Panel Votes to Loosen Restrictions for Four Peptides. July 2026. pharmexec.com
7. Quartz. FDA panel votes to ease restrictions on 6 peptides. July 28, 2026. qz.com
8. AJMC. FDA Panel Backs 6 Peptides for Compounding. July 31, 2026. ajmc.com
9. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625
10. McGuire F, Hughes E, Maak T, Cushman DM. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Appl Sci. 2026;16(12):6202. doi:10.3390/app16126202